Log in

NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, Forecast & News

$25.46
-1.17 (-4.39 %)
(As of 12/10/2019 06:00 AM ET)
Today's Range
$24.22
Now: $25.46
$26.83
50-Day Range
$15.83
MA: $20.47
$26.92
52-Week Range
$9.31
Now: $25.46
$27.40
Volume697,510 shs
Average Volume1.48 million shs
Market Capitalization$1.74 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.38
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DRNA
CUSIPN/A
Phone617-621-8097

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.18 million
Book Value$3.20 per share

Profitability

Net Income$-88,850,000.00
Net Margins-541.24%

Miscellaneous

Employees78
Market Cap$1.74 billion
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive DRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter.


Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) announced its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.15. The biopharmaceutical company earned $8.04 million during the quarter, compared to analyst estimates of $11.70 million. Dicerna Pharmaceuticals had a negative net margin of 541.24% and a negative return on equity of 58.92%. View Dicerna Pharmaceuticals' Earnings History.

When is Dicerna Pharmaceuticals' next earnings date?

Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Dicerna Pharmaceuticals.

What price target have analysts set for DRNA?

8 brokerages have issued 12-month price targets for Dicerna Pharmaceuticals' shares. Their forecasts range from $18.00 to $50.00. On average, they anticipate Dicerna Pharmaceuticals' share price to reach $29.43 in the next twelve months. This suggests a possible upside of 15.6% from the stock's current price. View Analyst Price Targets for Dicerna Pharmaceuticals.

What is the consensus analysts' recommendation for Dicerna Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dicerna Pharmaceuticals.

Has Dicerna Pharmaceuticals been receiving favorable news coverage?

News headlines about DRNA stock have trended somewhat negative recently, InfoTrie reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dicerna Pharmaceuticals earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Dicerna Pharmaceuticals.

Who are some of Dicerna Pharmaceuticals' key competitors?

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Array Biopharma (ARRY), Strongbridge Biopharma (SBBP), Exelixis (EXEL), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), Sorrento Therapeutics (SRNE), Ergomed (ERGO), Progenics Pharmaceuticals (PGNX) and Equity Commonwealth (EQC).

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the folowing people:
  • Dr. Douglas M. Fambrough III, Co-Founder, CEO, Pres & Director (Age 50)
  • Dr. Bob D. Brown, Chief Scientific Officer & Sr. VP (Age 54)
  • Dr. Ralf H. Rosskamp, Chief Medical Officer (Age 66)
  • Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory Board
  • Prof. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 72)

Who are Dicerna Pharmaceuticals' major shareholders?

Dicerna Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (2.61%), Eagle Asset Management Inc. (2.58%), Carillon Tower Advisers Inc. (1.64%), Emerald Advisers LLC (1.28%), Emerald Mutual Fund Advisers Trust (1.14%) and Millennium Management LLC (0.55%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bain Capital Life Sciences Inv, Brian K Halak, Dennis Langer, James B Weissman, John B Green and Peter Kolchinsky. View Institutional Ownership Trends for Dicerna Pharmaceuticals.

Which institutional investors are selling Dicerna Pharmaceuticals stock?

DRNA stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Barclays PLC, SG Americas Securities LLC, State Street Corp, Alps Advisors Inc. and Claro Advisors LLC. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bain Capital Life Sciences Inv, James B Weissman, John B Green and Peter Kolchinsky. View Insider Buying and Selling for Dicerna Pharmaceuticals.

Which institutional investors are buying Dicerna Pharmaceuticals stock?

DRNA stock was bought by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., Millennium Management LLC, Alberta Investment Management Corp, California Public Employees Retirement System, Squarepoint Ops LLC, Zurcher Kantonalbank Zurich Cantonalbank and California State Teachers Retirement System. View Insider Buying and Selling for Dicerna Pharmaceuticals.

How do I buy shares of Dicerna Pharmaceuticals?

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Dicerna Pharmaceuticals' stock price today?

One share of DRNA stock can currently be purchased for approximately $25.46.

How big of a company is Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals has a market capitalization of $1.74 billion and generates $6.18 million in revenue each year. The biopharmaceutical company earns $-88,850,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe.View Additional Information About Dicerna Pharmaceuticals.

What is Dicerna Pharmaceuticals' official website?

The official website for Dicerna Pharmaceuticals is http://www.dicerna.com/.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]


MarketBeat Community Rating for Dicerna Pharmaceuticals (NASDAQ DRNA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  344 (Vote Outperform)
Underperform Votes:  256 (Vote Underperform)
Total Votes:  600
MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe DRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel